⁶⁸Ga Fibroblast Activation Protein Inhibitor PET/CT in the Detection of Metastatic Thyroid Cancer: Comparison with ¹⁸F-FDG PET/CT.

Abstract

Background Gallium 68 (⁶⁸Ga)-labeled fibroblast activation protein inhibitor (FAPI) has been proposed as a potential radiotracer for visualizing cancerous lesions, but its utility for identifying metastatic differentiated thyroid cancer (DTC) is not well established in the literature. Purpose To evaluate the clinical utility of ⁶⁸Ga-FAPI PET/CT for detecting metastatic DTC and to compare the results with those of fluorine 18 (¹⁸F) fluorodeoxyglucose (FDG) PET/CT. Materials and Methods Participants with clinically suspected or confirmed metastatic DTC were prospectively enrolled and underwent paired ⁶⁸Ga-FAPI and ¹⁸F-FDG PET/CT from May to August 2020. Histopathologic results and clinical follow-up (mean, 12 months ± 0.7 [SD]; range, 11-13 months) were used as reference standards for the final diagnosis. ¹⁸F-FDG and ⁶⁸Ga-FAPI uptake was compared by using the Wilcoxon signed-rank test. The McNemar test was used to compare the diagnostic accuracy of the two techniques, and the influence of various clinicopathologic characteristics on ¹⁸F-FDG and ⁶⁸Ga-FAPI uptake was evaluated with Mann-Whitney and Kruskal-Wallis tests. Results In total, 35 participants (median age, 44 years; IQR, 28-58 years; 18 [51%] men) were evaluated. In all 35 participants, the ⁶⁸Ga-FAPI-derived maximum standardized uptake value (SUV_max) was higher than the ¹⁸F-FDG-derived SUV_max in the metastatic lateral compartment (6.0 vs 3.5; <i>P</i> = .001), axillary (8.5 vs 4.3; <i>P</i> = .01), mediastinal lymph nodes (9.1 vs 5.0; <i>P</i> = .001), and pulmonary metastases (1.7 vs 1.1; <i>P</i> = .004). ⁶⁸Ga-FAPI PET/CT had a higher sensitivity than ¹⁸F-FDG PET/CT for depicting neck lesions (83% [65 of 78; 95% CI: 73, 90] vs 65% [51 of 78; 95% CI: 54, 75], <i>P</i> = .01) and distant metastases (79% [87 of 110; 95% CI: 71, 86] vs 59% [65 of 110; 95% CI: 50, 68], <i>P</i> < .001). Conclusion Gallium 68-labeled fibroblast activation protein inhibitor PET/CT was superior to fluorine 18 fluorodeoxyglucose PET/CT for depicting metastatic differentiated thyroid cancer, especially in lymph nodes and pulmonary metastases. Published under a CC BY 4.0 license. <i>Online supplemental material is available for this article.</i>